Type2 diabetes
Conditions
Interventions
After switching from a DPP-4 inhibitor to oral Libersus 3 mg, oral administration was continued for more than 3 months, and oral medication adherence was good. After explaining the outline of the stud
7.0%.
After switching from a DPP-4 inhibitor to oral Libersus 3 mg, oral administration was continued for more than 3 months, and oral medication adherence was good. After explaining the outline of th
7.0% group.
Sponsors
Fuji City General Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Age> 18years. 2)HbA1c >7.0%, <10.5%. 3)Patients who are receiving DPP-4 inhibitors and have been switched to oral semaglutide 3 mg because the attending physician considers that treatment with a GLP-1 receptor agonist is necessary. 4) HbA1c levels 8-12 weeks prior to the start of treatment in this study must be measured and recorded. 5)Patients who fully understood and provided written consent based on their own free will after receiving a sufficient explanation for participation in this study. 6)Patients who have not started a new antidiabetic drug other than oral semaglutide or changed the dose for 12 weeks before consent.
Exclusion criteria
Exclusion criteria: 1) type 1 diabetes mellitus, 2) insulin-treated patients, 3) treated with a GLP-1 receptor agonist within 3 months prior to the introduction of oral semaglutide 3 mg, 4) severe ketosis within the past 6 months , persons with a history of diabetic coma, 5) women who are pregnant or may become pregnant, and those who are breast-feeding,6) persons suspected of having diabetes due to other specific mechanisms or diseases, 7) being on steroids , 8) malignant tumor, 9) severe infection, serious trauma, 10) ineligible to participate in the study as judged by the attending physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| We compared the patient characteristics and blood test findings between the achievement group and the non-achievement group in patients who needed to increase the oral semaglutide dose to 14 mg with the goal of HbA1c of less than 7.0%. | — |
Secondary
| Measure | Time frame |
|---|---|
| Investigation of the patient background of the achievement group and the non-achievement group and the amount of change in each blood test in patients whose HbA1c was less than 7.0% and required an increase in oral semaglutide dose to 14 mg | — |
Countries
Japan
Contacts
Public ContactTakao Hirotsu
Fuji City General Hospital Diabetes Endocrinology Hematology
Outcome results
None listed